Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits
Samhi Hotels stock made a subdued debut on the stock exchanges on September 22, listing at a premium of just 6.75% over the IPO price of Rs 126. The stock opened at Rs 134.50 on the NSE and Rs 130.55 on the BSE.
Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth. “Investors should book profit and exit their position,” said Shivani Nyati, Head of Wealth, Swastika Investmart Ltd.
Anushi Vakharia, Research Analyst at StoxBox, also advised investors to sell their shares on the opening day. “The stock opened near the issue price due to the company-specific characteristics such as loss-making status, negative net worth and increased borrowings,” she said.
Samhi Hotels IPO was subscribed 5.57 times, supported by qualified institutional buyers (QIBs). However, the issue did not receive enough support from high net-worth individuals (HNIs) and retail investors.
The company’s financial performance has been poor for the last three years, but it is making progress on cutting losses. The stock is currently trading at a sales multiple of 3.7X, which is below the industry average.
Overall, the outlook for Samhi Hotels stock is not very bright. Analysts recommend booking profits in the stock, given its loss-making status and negative net worth. Investors should consider other avenues for investment.
Related News
- 22 Sep
Signature Global IPO Subscribed 11.88 Times on Final Day
The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.
- 22 Sep
Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding
Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.
- 22 Sep
Pharma company Valiant Laboratories to go public on September 27
Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.
- 21 Sep
Unihealth Consultancy makes tepid debut on NSE Emerge
Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.
- 21 Sep
Signature Global IPO Subscription Update
Signature Global's IPO has received decent response from investors so far, with HNIs and retail investors being the most aggressive bidders. However, analysts advise investors to be cautious due to the company's history of losses and the fluctuating nature of the real estate industry.
Leave a Reply